APG 1387

Drug Profile

APG 1387

Alternative Names: APG-1387; SM-1387

Latest Information Update: 04 Oct 2016

Price : $50

At a glance

  • Originator Jiangsu Ascentage Pharma
  • Class Antineoplastics
  • Mechanism of Action Inhibitor of apoptosis protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Lymphoma; Solid tumours

Most Recent Events

  • 29 Sep 2016 Phase-I clinical trials in Solid tumours in China (IV) before September 2016
  • 29 Sep 2016 Ascentage Pharma plans clinical trial (In combination) for Breast cancer and Ovarian cancer
  • 18 May 2016 Phase-I development is ongoing in Australia
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top